{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-241546","form_type":"8-K","ticker":"XENE","cik":"0001582313","company_name":"Xenon Pharmaceuticals Inc.","filed_at":"2025-10-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.821685+00:00","generated_at":"2026-05-17T03:33:01.878038+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Xenon appoints Tucker Kelly as CFO; grants 225K options, 30K RSUs","bullets":["Tucker Kelly named CFO effective Oct 15, 2025; previously CFO at Deciphera (acquired by Ono for $2.4B).","Annual base salary $540K; eligible for incentive up to 45% of base.","One-time inducement grant: options for 225K shares at $41.90 (closing price Oct 15).","One-time grant of 30,000 RSUs; both options and RSUs vest over 4 years.","Interim CFO Ian Mortimer steps down but remains President & CEO as lead candidate azetukalner enters Phase 3."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-241546","json":"https://secwatch.observer/filing/0001193125-25-241546.json","markdown":"https://secwatch.observer/filing/0001193125-25-241546.md","text":"https://secwatch.observer/filing/0001193125-25-241546.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1582313/000119312525241546/0001193125-25-241546-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1582313/000119312525241546/xene-20251015.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T03:33:01.878038+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}